Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

ClinicalTrials.gov ID: NCT00464646

Public ClinicalTrials.gov record NCT00464646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer

Study identification

NCT ID
NCT00464646
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NSABP Foundation Inc
Network
Enrollment
105 participants

Conditions and interventions

Conditions

Interventions

  • Bevacizumab Drug
  • Cyclophosphamide Drug
  • Docetaxel Drug
  • Epirubicin Drug
  • Trastuzumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2007
Primary completion
Nov 30, 2009
Completion
Apr 30, 2014
Last update posted
Oct 24, 2021

2007 – 2014

United States locations

U.S. sites
35
U.S. states
21
U.S. cities
32
Facility City State ZIP Site status
Clearview Cancer Institute- Huntsville Huntsville Alabama 35801
Kaiser Permanente-San Diego San Diego California 92120
Kaiser Permanente-Vallejo Vallejo California 94589
CCOP, Colorado Cancer Research Program, Inc. Denver Colorado 80224
Baptist Regional Cancer Institute Jacksonville Florida 32207
Rush University Medical Center Chicago Illinois 60612
CCOP, Central Illinois Springfield Illinois 62526
CCOP, Northern Indiana Cancer Research Consortium South Bend Indiana 46601
University of Iowa Iowa City Iowa 52242
NortonHealtcare Inc. Louisville Kentucky 40202
CCOP, Grand Rapids Clnical Oncology Program Grand Rapids Michigan 49503
CCOP, Michigan Cancer Research Consortium Grosse Pointe Woods Michigan 48236
CCOP, Kalamazoo, MI Kalamazoo Michigan 49007
Michigan State University - Breslin Cancer Center Lansing Michigan 48910
CCOP, Metro-Minnesota Minneapolis Minnesota 55416
CCOP, Cancer Research for the Ozarks Springfield Missouri 65804
Cancer Institute of New Jersey New Brunswick New Jersey 08901
University Hospital and Medical Center - SUNY Stony Brook New York 11794
CCOP, Southeast Cancer Control Consortium Charlotte North Carolina 28203
East Carolina University Greenville North Carolina 27834
Aultman Hospital Canton Ohio 44710
Case Western Reserve/University Hospitals-Ireland Cancer Cntr. Cleveland Ohio 44106
CCOP, Dayton, OH Dayton Ohio 45429
CCOP, Columbia River Oncology Portland Oregon 97225
Kimmel Cancer Center at Jefferson Philadelphia Pennsylvania 19107
Albert Einstein Healthcare Network Philadelphia Pennsylvania 19141-3098
Allegheny General Hospital/Allegheny-Singer Research Institute Pittsburgh Pennsylvania 15212
NSABP Foundation, Inc. Pittsburgh Pennsylvania 15212
University of Pittsburgh Pittsburgh Pennsylvania 15213
Mercy Hospital Scranton Pennsylvania 18501
CCOP, Upstate Carolina Spartanburg South Carolina 29303
Joe Arrington Cancer Research & Treatment Center Lubbock Texas 79410
CCOP, Scott and White Memorial Hospital Temple Texas 76508
MBCCOP, Virginia Commonwealth University Richmond Virginia 23298
CCOP, Marshfield Clinic Marshfield Wisconsin 54449

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00464646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 24, 2021 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00464646 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →